The issuer is solely responsible for the content of this announcement.
(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United ...
United Biotechnology will retain the rights for UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan. United Biotechnology is eligible to receive an upfront payment of 200 million US dollars ...
Novo Nordisk and United Laboratories International’s subsidiary, United Biotechnology Co. have entered into a potentially $2 ...
United Biotechnology will retain the rights for UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan. United Biotechnology is eligible to receive an upfront payment of $200 million and ...
Novo Nordisk has decided that it wants its own triple agonist, and is willing to hand over $200 million upfront to United Laboratories’ subsidiary United Biotechnology. In return for the global ...
United Biotechnology will get $200M upfront, up to $1.8B in milestones, and royalties as part of its UBT251 licensing deal with Novo Nordisk A phase 1b trial of UBT251 showed a 15.1% weight loss ...
We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback